abrdn Healthcare Investors (HQH) Stock Analysis

Price updated 4 days ago · SEC data refreshed 3 months ago · Not investment advice

abrdn Healthcare Investors

HQH Unknown Unknown📄 SEC filings ↗
Valuation N/A
💵 Price $21.76 · 4 days ago 📄 Financials SEC EDGAR · refreshed 3 months ago

How to read HQH (pre-profit growth)

This company is reinvesting instead of generating profit, so a standard DCF cannot price it. The useful question is whether the growth the market is paying for is achievable — and whether the company can fund itself until then.

Where to start — the sections that matter most for this stock
  1. 1 Reverse-DCF — the growth the price demands ↓
    It shows exactly how fast the business must grow to justify today's price. Compare that to what comparable companies have actually achieved.
  2. 2 Cash runway ↓
    Can it reach profitability before it has to raise money and dilute shareholders?
  3. 3 Interactive calculator ↓
    Set your own growth + margin assumptions and see what the business would be worth if you are right.
Or — what are you trying to decide?
A note on process: fear-driven decisions — including fear of missing out — tend to be the expensive ones. A stock up 10% a day for three days is excitement, not evidence. Whichever reader you are, the data below is there to be checked before anything is decided.
🚀
"It's surging — should I chase it?"
The momentum / FOMO trade. Before you chase, see whether the people who know it best are quietly selling into the rally.
🏷️
"Is it a cheap bargain?"
The deep-value trade. How far below assets and our value it trades — and whether it's cheap for a reason.
ⓘ HQH is a thinly-disclosed company trading over-the-counter

It files little or nothing with the SEC — so our cash-flow models, financial statements, and U.S. insider data (Form 4) don't apply. What's still real: the live U.S. price and short positioning. Here's what we could pull from other sources:

📑 Read the real filings: latest SEC 8-K ↗

Identity, share count and tier from FINRA + OTC Markets; not a substitute for the home-market financial statements. Thin U.S. disclosure + OTC trading is itself a risk factor.

Loading insider & short-seller data…
Checking filings for failure warnings…

Quality & solvency checks

Cheap stocks can be cheap for a reason. These screens warn when a low valuation comes paired with structural fragility.

Altman Z-Score?Altman Z-Score — A bankruptcy-risk score combining 5 financial ratios into one number. Predictive of bankruptcy within 2 years.
Why it matters: Cheap-looking stocks (low P/E or P/B) often have low Z-scores because the market knows the company is dying. Z-score warns you before you fall into a value trap.
Reference: > 3.0 = safe zone · 1.81–3.0 = grey zone · < 1.81 = distress zone
Full explanation →
Not available for this filer

The Z-score needs working capital, retained earnings, EBIT, sales and total assets from the latest balance sheet, and at least one of those isn't reported in machine-readable form here — common for foreign private issuers. We leave it blank rather than compute a distress verdict from an estimated input. It doesn't affect the reported figures in the financial tables below.

Piotroski F-Score?Piotroski F-Score — A 9-point quality checklist scoring profitability, leverage, and operating efficiency.
Why it matters: High score = fundamentals improving. Low score = deteriorating. Especially powerful for filtering cheap stocks: cheap + high F-score historically outperforms; cheap + low F-score is often a value trap.
Reference: 7–9 = strong · 4–6 = mediocre · 0–3 = weak
Full explanation →
Not available for this filer

The F-score compares two consecutive years of income, cash-flow and balance-sheet data. We have 0 years of income data for this filer, but no machine-readable cash-flow statement or balance sheet — so several of the nine checks have no input at all. We show nothing rather than score a partial year against itself. The reported figures in the financial tables below are unaffected.

Price$21.76
Model IVNot applicable — DCF couldn't price this stock. The other valuation lenses on this page (reverse-DCF, peers, sector lens — whichever apply to this filer) carry the read instead.

A standard discounted cash flow?DCF — Discounted Cash Flow — sums up all future cash a business will produce, adjusted for the fact that future dollars are worth less than dollars today.
Why it matters: It is the most fundamentally honest valuation method when applicable — but only works for companies with predictable, positive cash flow.
Reference: Best for: mature, profitable businesses. Fails for: pre-profit growth, banks, REITs.
Full explanation →
(DCF) valuation is not meaningful for abrdn Healthcare Investors (HQH) because the model projects negative free cash flow?Free Cash Flow (FCF) — Operating cash flow minus capital spending: cash left after a company covers operating costs, taxes and interest and reinvests in the business — but BEFORE repaying debt principal or paying dividends. The cash actually available to investors.
Why it matters: A company can show big profits on paper while burning through cash. FCF is what actually fills the bank account.
Reference: Healthy mature businesses convert 8–15% of revenue into FCF · Growth companies often negative
Full explanation →
, indicating it is not currently generating profits. Valuing this company would require a focus on its investment portfolio's performance and the potential for capital appreciation from its healthcare holdings. Investors are likely betting on the long-term growth of the healthcare sector and the fund's ability to select outperforming assets. The number one quantifiable risk is the 'Franchise/durability score 0/5', suggesting a lack of sustainable competitive advantage or predictable cash flows.

⚠️ FCF negative: revenue/margin growth model projects future cash flows from revenue trajectory.

As of 3 months ago

Anatomy of a share

What you're buying per share. Bars are at the same scale so you can see the relative size of revenue, costs, cash flow, and debt — not just read them in a table.

Per-share economics aren't reliable for this filer. Its income statement or share count isn't fully reported to SEC EDGAR (common for foreign private issuers and thinly-disclosed OTC names), so we don't break it down per share here — the figures would be misleading. See the financial tables below for what is reported.

What you actually need to decide

Every stock price is a disagreement. Here's the single thing that must go right for the bulls, the single thing that breaks the thesis, and the concrete signposts to watch so you can update your view as real results arrive.

🐂 The Bull Case
The fund's portfolio companies must achieve significant breakthroughs or market share gains, leading to substantial capital appreciation, to overcome the 'FCF?Free Cash Flow (FCF) — Operating cash flow minus capital spending: cash left after a company covers operating costs, taxes and interest and reinvests in the business — but BEFORE repaying debt principal or paying dividends. The cash actually available to investors.
Why it matters: A company can show big profits on paper while burning through cash. FCF is what actually fills the bank account.
Reference: Healthy mature businesses convert 8–15% of revenue into FCF · Growth companies often negative
Full explanation →
negative' signal and generate positive returns.
🐻 The Bear Case
If the underlying healthcare investments underperform or face significant regulatory hurdles, the 'Franchise/durability score 0/5' implies a lack of intrinsic value?Intrinsic Value — Our DCF model's estimate of what each share is mathematically worth based on projected cash flows.
Why it matters: Compare to current price. Below IV = potentially undervalued. Above IV = priced for growth that must actually happen.
Reference: Model-derived; quality depends on data and assumptions.
Full explanation →
to cushion against portfolio losses, leading to continued negative free cash flow?Free Cash Flow (FCF) — Operating cash flow minus capital spending: cash left after a company covers operating costs, taxes and interest and reinvests in the business — but BEFORE repaying debt principal or paying dividends. The cash actually available to investors.
Why it matters: A company can show big profits on paper while burning through cash. FCF is what actually fills the bank account.
Reference: Healthy mature businesses convert 8–15% of revenue into FCF · Growth companies often negative
Full explanation →
and potential capital erosion.
📌 Signposts to watch — update your view as these print
  • Performance of key portfolio holdings
  • Changes in healthcare sector growth outlook
  • Fund's net asset value (NAV) trends

Management & Leadership

abrdn Healthcare Investors (HQH) is managed by abrdn Inc., a global investment company. The specific fund manager for HQH is not readily available as a named individual in public data, but abrdn Inc. is led by Stephen Bird as CEO, who has been in the role since September 2020. The fund operates as a closed-end investment company.

Stephen Bird
Chief Executive Officer, abrdn Inc.

What They Make

abrdn Healthcare Investors (HQH) is a closed-end investment company that invests primarily in equity securities of healthcare companies. Its objective is to provide long-term capital appreciation through investments in the global healthcare industry.

End Markets

PharmaceuticalsBiotechnologyMedical Devices

Revenue Drivers

Portfolio investment gains
Dividend income from holdings
Interest income from holdings
Beta: 0.86

Why Is It Priced Like This?

Why Customers Pay

Exposure to global healthcare sector
Professional portfolio management
Diversification within healthcare
No discounted-cash-flow value for this filer No machine-readable cash-flow statement in this filer's EDGAR submissions — common for foreign private issuers (20-F/6-K). That makes a discounted-cash-flow valuation impossible: there is no free cash flow to discount. It does not affect the income-statement or balance-sheet figures below.

The income statement and balance sheet are also too incomplete here to substitute another lens honestly, so this page carries price, momentum and disclosure facts only.

The market is likely pricing HQH based on the perceived growth potential of its underlying healthcare investments, rather than its current cash flows, which are projected to be negative. The 'Franchise/durability score 0/5' indicates that the market is not assigning value to a sustainable competitive advantage from the fund itself, but rather to the optionality of its portfolio companies' drug pipelines or regulatory approvals, which are not captured in a backward-looking cash flow model. The market may be assigning value to future breakthroughs in biotech and pharma, which is not in the model.

Business Model & Valuation

How They Make Money

Investing in global healthcare equities
Generating capital appreciation from portfolio
Distributing income from investments

As a closed-end fund, HQH typically funds itself through initial share offerings and reinvests portfolio gains, with distributions to shareholders from investment income.

Growth / Revenue DCF

No cash flow statement data available - using revenue/margin growth model as fallback.

Show advanced inputs
Revenue Growth15.0%

What this model does NOT do: this is a consolidated owner-earnings FCF model. Standalone segment assumptions: none. It does not project its revenue segments independently; their combined effect is embedded in the historical revenue and cash-flow trend the model extrapolates. The calculator above can only approximate a segment's impact through the single consolidated growth rate — it cannot model any one line separately. For a true segment-level view, build a separate model from the company's segment disclosures.

Maturity & Competitive Position

Growth / re-investment phase

Moat Signals

Access to specialized healthcare research
Diversified global healthcare exposure
Experienced investment management team

Geography & Markets

abrdn Healthcare Investors (HQH) invests in the global healthcare industry. While specific geographic mix percentages are not available, its mandate suggests a diversified international exposure beyond just the US market.

Geographic Risks

Concentration risk in healthcare sector
Global economic and regulatory risks affecting portfolio companies

Market Signals

These are timing signals, not value signals — they describe the stock's recent price behavior, not what the business is worth. Use them for the "the thesis looks good, but is now the moment?" question. Each tile below explains what it's saying.

Model neutral, tape bullish
RSI?RSI — Relative Strength Index — a 0-100 momentum gauge. Above 70 = overbought; below 30 = oversold.
Why it matters: Short-term contrarian indicator. Extreme readings often precede mean reversion, though not always.
Reference: 30–70 normal · >70 overbought · <30 oversold
Full explanation →
(14)
56.1NeutralMomentum is balanced — neither overbought nor oversold.
MACD?MACD — Moving Average Convergence Divergence — compares a fast and a slow price trend to gauge momentum direction.
Why it matters: When the fast line crosses above the slow line, short-term momentum is turning up; below, turning down. A timing cue, not a value signal.
Reference: Line above signal = bullish momentum · below = bearish
Full explanation →
BearishLine below signalThe fast trend is below the slow trend — short-term momentum is currently downward.
50-Day Average$19.25Price above (+13.0%)Price above its 50-day average = near-term uptrend.
200-Day Average$18.67Price aboveThe 200-day line is the long-term trend divider — above it is generally considered a bull market for the stock.
50 vs 200 CrossGolden50-day above 200-dayA "golden cross" — the medium trend has overtaken the long trend (often read as bullish).

Technicals describe price, not the business. A great company can have a "bearish" tape (a buying chance) and a weak one a "bullish" tape (a trap). Pair these with the valuation and health sections above.

Data Quality & Risk Flags (8 notes — click to expand/collapse)

Guardrail Notes (8)
  • FCF negative: revenue/margin growth model projects future cash flows from revenue trajectory.
  • INVARIANT: weighted IV is non-positive. Model may not be appropriate.
  • Model implies no positive equity value under these assumptions. Valuation is speculative/low-confidence.
  • Shares from unknown — per-share values may be less accurate.
  • Illiquidity discount 25% applied (small/micro-cap — harder to exit, demand a margin).
  • Shares/market cap missing or defaulted; per-share valuation unreliable.
  • Shares defaulted to 1; IV is NOT meaningful — treat as data-unavailable.
  • DATA UNAVAILABLE: per-share values suppressed due to missing/unreliable shares data.

Financial Statements (5-year tables — click to expand)

From abrdn Healthcare Investors's SEC filings (EDGAR).

Similar companies worth a look

Same sector and industry, similar fundamentals shape. Verify everything yourself — this list is computed mechanically and does not reflect our judgment about whether any of these are a good investment.

PG
Methodology by Pouyan Golshani, MD — founder of Gighz. Savng was built by a physician for busy professionals: every number on this page comes from SEC filings (EDGAR) and FINRA data through transparent, rules-based models — no analyst opinions, no hidden inputs. How we calculate every number →
⚠️ Not investment advice. Automated model outputs, last refreshed May 30, 2026 (the analysis-refresh date, not the latest filing period). All models have blind spots. Full disclaimer →
🔔 Follow $HQH — free insider alerts
One email when an insider buys $HQH on the open market with their own cash — or notably sells outside a scheduled plan. Routine and automated trades filtered out. Follow up to 3 stocks free; Portfolio Watch covers your whole list plus valuation & risk alerts. Double opt-in, unsubscribe anytime.